Abscess

NADP Advocates for Improved Access to Dental Benefits and Care

Retrieved on: 
月曜日, 5月 20, 2024
HealthCare.gov, NADP, Patient, Marketplace, Hospital, Abscess, DHHS, DOC, Optometry, NCS, Access, Congress, National Association, Health insurance

The fix would enable consumers to purchase dental benefits without first having to purchase medical coverage.

Key Points: 
  • The fix would enable consumers to purchase dental benefits without first having to purchase medical coverage.
  • The current technical design of the Marketplaces links medical and dental enrollment functions on HealthCare.gov, preventing the independent purchase of dental coverage.
  • “NADP commends our members for advancing our mission to improve access to affordable, quality dental care in 77 meetings with Congressional leaders and their staff,” said Board Chair Donna Hunter, United Concordia Dental.
  • NADP members opposed a non-covered services (NCS) bill, Dental and Optometric Care (DOC) Access, which would diminish the value of patients’ dental coverage by increasing their out-of-pocket expenses.

Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey

Retrieved on: 
木曜日, 5月 9, 2024
Pain, Euthanasia, Animal, Inflammation, Laminitis, AB, Female, Disease, Human, Therapy, Amputation, Patient, Caregiver, Abscess, Horse

Miri, a 7-year-old female donkey, underwent amputation of her right front limb at a young age, resulting in a weight burden primarily borne by her left front limb.

Key Points: 
  • Miri, a 7-year-old female donkey, underwent amputation of her right front limb at a young age, resulting in a weight burden primarily borne by her left front limb.
  • As an act of compassionate therapy, the female donkey was administered a liposomal-CBD injection.
  • "Thanks to our innovative liposomal-CBD injection, we are thrilled to have brought relief to Miri, eliminating the need for euthanasia," commented Iris Bincovich, CEO of Innocan.
  • "Laminitis is a crippling condition well familiar and common in horses," said Prof Chezy Barenholz, the Chief Scientific Officer of Innocan.

ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones

Retrieved on: 
木曜日, 5月 9, 2024
Psoriatic arthritis, Hyperglycemia, Graves' ophthalmopathy, Abscess, Huber loss, Risk, QW, Hidradenitis suppurativa, Conference, Webcast, Suicidal ideation, Development, MRCP, Disease, Patient, Fungus, LOS, SLRN, Diplopia, FRCP, IL-17A, POC, CAS, Quality of life, Exophthalmos, Behavior, Infection, Pharmaceutical industry

LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today provided an update on various corporate milestones.

Key Points: 
  • This Phase 2b/3 trial, designed to be the first of two registrational trials in TED, is planned to be initiated in the second half of 2024.
  • Izokibep in Uveitis (UV): ACELYRIN expects to complete enrollment in the ongoing Phase 2b/3 trial this month and top line data are anticipated by year-end 2024.
  • ACELYRIN expects to report cash, cash equivalents, and short-term marketable securities of $678.5 million at March 31, 2024.
  • Gil Labrucherie, who serves as ACELYRIN’s Chief Financial Officer, has also been named Chief Business Officer in addition to Chief Financial Officer.

Colon Rectal MD Announces New Robotic Colorectal Surgery Practice in Broward County

Retrieved on: 
月曜日, 4月 29, 2024
Colorectal surgery, Ulcerative colitis, Abscess, Colorectal cancer, Crohn's disease, General surgery, Suite, Hemorrhoid, Diverticulitis, Cancer, Fecal incontinence, Inflammatory bowel disease, Patient, Rectal prolapse, Colonoscopy, Anal, Diagnosis, Patient satisfaction, Quality of life, Gallbladder disease, Hospital

FORT LAUDERDALE, Fla., April 29, 2024 /PRNewswire-PRWeb/ -- Dr. Astha Bhatt, a leading board-certified general surgeon and fellowship-trained specialist in Minimally Invasive Colorectal surgery. We announce the opening of her new practice, Colon Rectal MD, in Broward County, Florida. Dr. Bhatt's practice focuses on providing personalized care utilizing the latest in robotic and laparoscopic technology.

Key Points: 
  • We announce the opening of her new practice, Colon Rectal MD, in Broward County, Florida.
  • Dr. Bhatt's practice focuses on providing personalized care utilizing the latest in robotic and laparoscopic technology.
  • Colon Rectal MD distinguishes itself by utilizing the da Vinci robotic system, enhancing surgical accuracy and facilitating faster patient recovery.
  • This advanced approach places Dr. Bhatt at the forefront of colorectal surgery, and general surgery particularly in treating Colon Cancer, Rectal Cancer, pelvic floor disorders, and inflammatory bowel disease.

ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights

Retrieved on: 
木曜日, 3月 28, 2024
Research, IL-17A, Strategic planning, Cell, Exophthalmos, Disease, Infection, Fungus, Risk, Inflammation, SLRN, Patient, Psoriatic arthritis, Acquisition, Doctor of Philosophy, MD, Quality of life, CAS, Senior, IPR, Eye, NeoGenomics, Graves' ophthalmopathy, Suicidal ideation, Behavior, Hidradenitis suppurativa, QW, Drug development, LOS, Corporate communication, Abscess, Diplopia, Pharmaceutical industry

LOS ANGELES, March 28, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today reported financial results for the full year ended December 31, 2023 and highlighted recent corporate updates and upcoming milestones.

Key Points: 
  • R&D Expenses: Research and development expenses were $355.9 million for the full year ended December 31, 2023, as compared to $55.6 million for 2022.
  • G&A Expenses: General and administrative expenses were $66.2 million for the full year ended December 31, 2023, as compared to $13.5 million for 2022.
  • Net Loss: Net loss for the full year ended December 31, 2023 was $381.6 million, compared to $64.8 million for 2022.
  • In December 2023, the Company announced the appointment of Lynn Tetrault to its Board of Directors.

Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa

Retrieved on: 
日曜日, 3月 10, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Patient, AAD, HS, Abscess, American Academy, Safety

Incyte (Nasdaq:INCY) today announced new results from a Phase 2 study evaluating the efficacy and safety of twice-daily ruxolitinib cream 1.5% (Opzelura®) in adult patients with Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa (HS).

Key Points: 
  • Incyte (Nasdaq:INCY) today announced new results from a Phase 2 study evaluating the efficacy and safety of twice-daily ruxolitinib cream 1.5% (Opzelura®) in adult patients with Hurley stage 1 or 2 (mild-to-moderate) hidradenitis suppurativa (HS).
  • Treatment-emergent adverse events (TEAEs) occurred in 38.2% of patients who applied ruxolitinib cream 1.5% versus 42.9% of patients who applied vehicle control.
  • The most common TEAEs among patients receiving ruxolitinib cream 1.5% were COVID-19 (5.9%) and nasopharyngitis (5.9%).
  • Discontinuation due to TEAEs were infrequent (ruxolitinib cream 1.5%, n=2 [5.9%]; vehicle control, n=0 [0%]), and no serious TEAEs were reported in the ruxolitinib cream 1.5% group.

ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients

Retrieved on: 
月曜日, 3月 11, 2024
Psoriatic arthritis, INC, Doctor of Philosophy, LOS, MD, SLRN, FDA, Quality of life, Pain, Infection, DLQI, Suicidal ideation, Abscess, Risk, Behavior, Safety, Hidradenitis suppurativa, Fungus, Patient, Medicine, IL-17A

LOS ANGELES, March 11, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced long-term data from a Phase 2b clinical trial of izokibep in hidradenitis suppurativa (HS). These data demonstrated no evidence of increased safety liability with longer-term treatment and increased duration of therapy was associated with further clinical improvements over time.

Key Points: 
  • (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced long-term data from a Phase 2b clinical trial of izokibep in hidradenitis suppurativa (HS).
  • These data demonstrated no evidence of increased safety liability with longer-term treatment and increased duration of therapy was associated with further clinical improvements over time.
  • “The magnitude and depth of responses for signs and symptoms of Hidradenitis Suppurativa in this long-term study are consistent with izokibep’s mechanism of action.
  • A confirmatory phase 3 trial of approximately 400 patients is planned to address guidance on size of safety database given the FDA no longer considers moderate-to-severe HS an orphan disease.

Medicines360 and DKT WomanCare Announce Strategic Partnership to Expand Access to the Hormonal IUD Avibela™

Retrieved on: 
水曜日, 1月 31, 2024
SAN, Nausea, Clinical trial, Perforation, Birth, Fibroid, Internal bleeding, Liver failure, Infection, Artery, Pelvic pain, DKT International, Jaundice, Anticoagulant, Blood pressure, Ovarian cyst, Woman, Acne, Organization, Partnership, Endometritis, Angioedema, History, Abscess, Contraindication, DKT, Peritonitis, Rash, Coagulopathy, Dyspareunia, Inflammatory cytokine, Adhesion, Vomiting, Bacterial vaginosis, Headache, Bowel obstruction, IUS, Uterus, STI, Breast cancer, Miscarriage, Patient, Fertility, Sepsis, Marketing, Risk, Stroke, Organ, Streptococcus, Hormone-sensitive cancer, Liver tumor, Cyst, Intrauterine device, GAS, Pregnancy, PID, Social marketing, Vaginitis, Migraine, Myocardial infarction, Health, Brain, Birth control

"As a global nonprofit pharmaceutical organization dedicated to expanding access to affordable reproductive health products for women, DKT WomanCare is an ideal partner for our organization," said Dr. Andrea Olariu, CEO of Medicines360.

Key Points: 
  • "As a global nonprofit pharmaceutical organization dedicated to expanding access to affordable reproductive health products for women, DKT WomanCare is an ideal partner for our organization," said Dr. Andrea Olariu, CEO of Medicines360.
  • “DKT WomanCare looks forward to leveraging our global partnerships and commercial relationships to ensure every woman, regardless of income, can access affordable, high-quality contraception.
  • As the supplier of AVIBELA, Medicines360 will focus on providing quality assurance and regulatory oversight, as well as ensuring sustainable product supply to DKT WomanCare and global procurement agencies.
  • Together, Medicines360 and DKT WomanCare will meet the growing demand for quality-assured, affordable hormonal IUDs and help build a robust and sustainable global contraceptive market.

Acelyrin (SLRN) Investor Update: Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
水曜日, 1月 17, 2024
Patient, Part, SLRN, Kaplan Fox, Complaint, HS, FOX, Abscess, News

NEW YORK, NY - ( NewMediaWire ) - January 16, 2024 - Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired Acelyrin, Inc. (“Acelyrin” or the “Company”) (NASDAQ: SLRN) securities between May 4, 2023 and September 11, 2023, inclusive (the “Class Period”).

Key Points: 
  • NEW YORK, NY - ( NewMediaWire ) - January 16, 2024 - Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired Acelyrin, Inc. (“Acelyrin” or the “Company”) (NASDAQ: SLRN) securities between May 4, 2023 and September 11, 2023, inclusive (the “Class Period”).
  • If you purchased Acelyrin securities and would like to discuss this notice, your rights, or your interests please click here .
  • WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.
  • For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com .

FINAL DEADLINE REMINDER FOR SLRN INVESTORS: Kessler Topaz Meltzer & Check, LLP Announces Final Lead Plaintiff Deadline in Securities Class Action Lawsuit Filed Against Acelyrin, Inc. (SLRN)

Retrieved on: 
月曜日, 1月 15, 2024
Contract research organization, Patient, LLP, Part, Insurance, SLRN, District court, Court, COPY, Abscess, IPO, News, Lead, Pharmaceutical industry

Kessler Topaz Meltzer & Check, LLP encourages Acelyrin investors who have suffered significant losses to contact the firm directly to acquire more information.

Key Points: 
  • Kessler Topaz Meltzer & Check, LLP encourages Acelyrin investors who have suffered significant losses to contact the firm directly to acquire more information.
  • A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation.
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.
  • Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.